EGFR and non-small cell lung carcinoma: In the 2020 ADAURA primary analysis, adjuvant osimertinib demonstrated a substantial improvement in disease-free survival (DFS) compared to placebo for individuals with EGFR-mutated NSCLC who had undergone complete tumor resection, regardless of prior adjuvant chemotherapy.